
Stiefel and Welichem Biotech have entered into an agreement for Stiefel’s acquisition of exclusive development and commercialization rights to the nonsteroidal, topical anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.